Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

31,220 signal articles · 69 in last 24h · 160,072 total before filter · latest 1h ago
69last 24h
813last 7d
120● bullish (7d)
82● bearish (7d)
214publishers
AllMacro164Earnings200M&A86Regulatory15Product14Analyst25
✕ clear all filtersticker: NVDASentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Nvidia (NVDA) Backs Verkada And Brings In A Microsoft Veteran To Lead Sales
Simply Wall St.88d agoneutral
Nvidia (NVDA) Backs Verkada And Brings In A Microsoft Veteran To Lead Sales

NVIDIA (NasdaqGS:NVDA) announced a new collaboration with Verkada to accelerate physical AI adoption in real world environments. NVIDIA will become a strategic investor in Verkada and work on AI search and safety applications for buildings and other physical spaces. The company also appointed former Microsoft executive Nicholas Parker as EVP, Worldwide Field Operations, signaling a change in its go to market leadership. NVIDIA enters this news cycle with its stock at $194.83 and very large...

FEPI’s 25% Yield Masks a Painful Truth About Call-Writing Income
24/7 Wall St.88d agoneutral
FEPI’s 25% Yield Masks a Painful Truth About Call-Writing Income

The REX FANG & Innovation Equity Premium Income ETF (NASDAQ:FEPI) is one of the most aggressive volatility-income products on the market, selling calls against a concentrated basket of AI and mega-cap tech names to fund weekly cash distributions. Recent payouts have run roughly $0.21 per week against a share price of about $42, which annualizes ... FEPI’s 25% Yield Masks a Painful Truth About Call-Writing Income

Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly
24/7 Wall St.89d agoneutral
Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly

Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) just reported Q1 2026 results that read like two different playbooks for winning in healthcare. Lilly is riding a GLP-1 wave. JNJ is proving that a wide, refreshed portfolio can still compound. Both raised guidance and both are worth putting side by side right now. GLP-1 Fireworks ... Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly

Procter & Gamble vs Colgate-Palmolive: Two Consumer Giants, Two Strategies, One Invests, Other Optimizes
24/7 Wall St.89d agoneutral
Procter & Gamble vs Colgate-Palmolive: Two Consumer Giants, Two Strategies, One Invests, Other Optimizes

Procter & Gamble (NYSE:PG) and Colgate-Palmolive (NYSE:CL) both posted top and bottom line beats in their most recent quarters. PG’s fiscal Q3 2026 leaned on Beauty and broad regional strength. Colgate’s Q1 2026 leaned on Latin America and Hill’s Pet. Same shelf, very different engines. Beauty Powers P&G. Latin America Powers Colgate. P&G’s headline was ... Procter & Gamble vs Colgate-Palmolive: Two Consumer Giants, Two Strategies, One Invests, Other Optimizes

Why Arm Is a Strong Buy Despite the 35% Pullback From Peak Levels
24/7 Wall St.89d agobullish
Why Arm Is a Strong Buy Despite the 35% Pullback From Peak Levels

Arm Holdings (NASDAQ:ARM) has been one of 2026’s most dramatic stories, ripping from a January low near $105 to a record $452.70 in June before giving back gains. With shares now near $315, the question is whether the AI CPU thesis still has room to run or if the easy money has already been made. ... Why Arm Is a Strong Buy Despite the 35% Pullback From Peak Levels